RCKT Investors Sue Over Trial Death Fallout

Rocket Pharmaceuticals told investors its lead gene therapy was ready for liftoff; but in the end it failed to launch.  After failing to disclose a major study change that led to a patient’s death and an FDA clinical hold, Rocket’s stock crashed 37%. Now, investors are suing.

In early 2025, Rocket hyped its RPA-501 drug for Danon disease, promising strong safety data and a clear path to FDA approval.  Behind the scenes, the skies were cloudy.  Rocket secretly changed its trial protocol without telling investors. Then, in May, a patient who received updated treatment died from complications.

The FDA immediately grounded the entire trial. Investors didn’t wait. They dumped their shares, and Rocket’s stock collapsed.

Now, more shareholders are joining the lawsuit.